Two products. One molecule. Two different FDA approvals, two different clinical populations, two different price structures, and two different insurance coverage landscapes. The confusion patients and clinicians encounter with Zepbound and Mounjaro is not incidental—it reflects a deliberate pharmaceutical regulatory strategy that has real consequences for who can access tirzepatide and at what cost.
The Regulatory Architecture
Tirzepatide is the active molecule. Eli Lilly holds two separate FDA approvals for the same molecule:
- Mounjaro (tirzepatide): approved June 2022 for type 2 diabetes management, as an adjunct to diet and exercise
- Zepbound (tirzepatide): approved November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
The doses available, the formulations, and the pen delivery devices are identical. The indications, the labeled populations, and the coverage pathways are not. This matters because insurance coverage in the United States is gatekept by diagnosis, not by drug chemistry. A patient with type 2 diabetes whose plan covers Mounjaro may not be covered for Zepbound at the same dose for the same underlying weight problem—even though the medication is chemically identical.
Clinical Evidence: Is the Data Different?
The pivotal trial programs are distinct, which is appropriate because the approved populations are distinct. Mounjaro’s approval rested on the SURPASS trials, which evaluated tirzepatide in adults with type 2 diabetes against placebo and active comparators including insulin degludec, insulin glargine, semaglutide 1 mg, and dulaglutide. The primary endpoints were HbA1c reduction and safety.
Zepbound’s approval rested on the SURMOUNT trials, which evaluated tirzepatide in adults with obesity or overweight without type 2 diabetes (SURMOUNT-1 and 2) and in specific subpopulations including those with obstructive sleep apnea (SURMOUNT-3). The primary endpoints were percentage weight change and proportion of patients achieving predefined weight loss thresholds.
Key outcomes by trial program
- SURPASS-2 (Mounjaro vs semaglutide 1 mg, T2D): tirzepatide 15 mg reduced HbA1c by 2.58% vs 1.86% for semaglutide; weight loss 12.4 kg vs 6.2 kg
- SURMOUNT-1 (Zepbound, no T2D): tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks; 57% of participants lost ≥20% body weight
- SURMOUNT-OSA (Zepbound, sleep apnea): tirzepatide reduced apnea-hypopnea index by 27.4 events/hour vs 4.8 placebo; led to first FDA approval of a medication specifically for obesity-related OSA
What the data says about patients with both diabetes and obesity
Most patients who are candidates for tirzepatide have some degree of both metabolic dysregulation and excess adiposity. SURMOUNT-2 specifically enrolled adults with type 2 diabetes alongside obesity and found mean weight loss of 15.7% at the 15 mg dose. This sits between the Mounjaro SURPASS-2 data and the SURMOUNT-1 non-diabetes population, which is clinically coherent: diabetes attenuates weight loss response to GLP-1 and dual agonist therapies.
Understanding which indication is documented in your medical record affects which drug name your plan may cover.
Compare Available Programs →Coverage: Why the Name on the Label Matters
The coverage implications are significant and often counterintuitive. A patient with both type 2 diabetes and obesity may find that their insurer covers Mounjaro for the diabetes indication—but not Zepbound for the weight management indication—despite the drugs being identical. Conversely, a patient without diabetes who is prescribed Mounjaro off-label for weight management may face a coverage denial because the submitted diagnosis does not match the approved indication on file.
This creates a system in which the prescribing physician’s documentation of the indication—not the clinical judgment about which medication to use—determines coverage. Physicians who understand this will document the indication most likely to be covered by the patient’s specific plan before submitting a prior authorization.
| Product | Approved Indication | Typical Coverage | Retail Price/Mo |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | Most commercial plans with T2D coverage | ~$1,029 |
| Zepbound | Chronic weight management | Plans with anti-obesity drug benefit (fewer) | ~$1,059 |
| Compounded tirzepatide | N/A (not FDA-approved) | Not covered; cash-pay only | $200–$500 |
Dose Escalation and Pen Differences
Both Mounjaro and Zepbound use the same KwikPen autoinjector system and are available in the same dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The recommended starting dose for both indications is 2.5 mg weekly for four weeks, then escalation by 2.5 mg every four weeks as tolerated.
There is no pharmacological reason to expect different outcomes from Mounjaro versus Zepbound at the same dose. The same molecule, same dose, same delivery system. Any difference in observed outcomes between the trial programs reflects the different enrolled populations, not product differences.
Compounded Tirzepatide: A Third Path
During periods when Zepbound and Mounjaro faced supply shortages, the FDA’s shortage list permitted licensed compounding pharmacies to produce tirzepatide. As of early 2026, FDA has indicated that the shortage designation for tirzepatide has been resolved, which has created regulatory uncertainty around the continued availability of compounded tirzepatide. The status of compounded tirzepatide access continues to evolve and may differ by state and individual compounding pharmacy.
Regulatory note: The availability of compounded tirzepatide is subject to FDA shortage list determinations and state pharmacy board rules that change. Patients accessing compounded tirzepatide should verify that their compounding pharmacy is state-licensed and operating within current FDA guidance. Compounded medications are not FDA-approved and are not subject to the same manufacturing standards as Mounjaro or Zepbound.
Which Name Should Patients Use?
Practically, the answer depends on the patient’s primary diagnosis. Patients with type 2 diabetes should work with their prescribing physician to determine whether Mounjaro coverage is available through their plan. Patients without diabetes who are seeking weight management should understand that Zepbound is the appropriate labeled product, and that coverage depends on their plan’s anti-obesity drug benefit.
Patients who lack coverage for either product, or who find the cost-sharing prohibitive, may consider cash-pay telehealth programs. The choice between compounded tirzepatide and brand-name Zepbound or Mounjaro involves both cost and clinical considerations that a licensed physician can help weigh.
Which tirzepatide pathway applies to your situation?
Patients seeking to understand which GLP-1 programs—including tirzepatide options—are available in their state at their budget may find a structured comparison useful before their physician consultation.
Compare My Options →Sources & References
- FDA. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company, 2023.
- FDA. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company, 2022.
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM, 2021.
- Jastreboff AM et al. Tirzepatide for Obesity (SURMOUNT-1). NEJM, 2022.
- Wharton S et al. Tirzepatide for Obesity with Obstructive Sleep Apnea (SURMOUNT-OSA). NEJM, 2024.
- FDA. Shortage List Determination for Tirzepatide. U.S. Food and Drug Administration, 2025.
Medical disclaimer: This article is for informational purposes only. Tirzepatide is a prescription medication requiring evaluation by a licensed physician. Coverage determinations are made by individual health plans and are subject to change. DawaMed is not a medical provider and does not prescribe medications.